Skip to main
PSTV
PSTV logo

PSTV Stock Forecast & Price Target

PSTV Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Plus Therapeutics Inc. is advancing its development in the oncology space with a significant focus on CNS cancers, notably through its candidate rhenium (186Re) obisbemeda. Positive developments include the receipt of an $18 million grant for studying leptomeningeal metastases and strategic expansions of its CNSide Diagnostics platform, which have bolstered operational capabilities and broadened market access. These advancements, combined with anticipated milestones and data releases expected in 2025/26, support a favorable long-term outlook for the company’s stock, as they enhance its commercial potential and operational scalability.

Bears say

Plus Therapeutics Inc faces significant risks that contribute to a negative outlook on its stock, primarily revolving around the potential failure of its product candidates, including rhenium (186Re) obisbemeda, to demonstrate safety and efficacy in clinical trials. Additionally, the company may struggle to secure regulatory approval for commercial sale, as well as suitable reimbursement, which could hinder its revenue generation prospects. Furthermore, increased competition in the oncology market and shifting macroeconomic conditions could further exacerbate the challenges Plus Therapeutics faces in achieving its financial objectives.

PSTV has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Plus Therapeutics Inc (PSTV) Forecast

Analysts have given PSTV a Strong Buy based on their latest research and market trends.

According to 4 analysts, PSTV has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Plus Therapeutics Inc (PSTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.